Rosetta Genomics Ltd. Files for Initial Public Offering

Sep 07, 2006, 01:00 ET from Rosetta Genomics Ltd

    REHOVOT, Israel, September 7 /PRNewswire/ -- Rosetta Genomics today
 announced that it has filed a registration statement with the Securities
 and Exchange Commission relating to the proposed initial public offering of
 its ordinary shares. Rosetta intends to sell 3,000,000 ordinary shares at a
 proposed initial public offering price of between $11.00 and $13.00 per
 share. Rosetta also expects to grant the underwriters a 30-day option to
 purchase up to an additional 450,000 shares to cover over-allotments, if
     C.E. Unterberg, Towbin, LLC is acting as the lead manager and the sole
 bookrunner for this offering. Oppenheimer & Co. Inc. and Maxim Group LLC
 are co-managers for this offering.
     Copies of the written preliminary prospectus related to the offering
 may be obtained from C.E. Unterberg, Towbin's syndicate department at 350
 Madison Avenue, 10th Floor, New York, New York 10017 (telephone:
     A registration statement relating to these securities has been filed
 with the Securities and Exchange Commission, but has not yet become
 effective. These securities may not be sold nor may offers to buy be
 accepted prior to the time the registration statement becomes effective.
     About Rosetta Genomics
     Rosetta Genomics is seeking to develop and commercialize new diagnostic
 and therapeutic products based on a recently discovered group of genes
 known as microRNAs, which are believed to play an important role in
 regulating protein production. Rosetta has developed an early and strong
 intellectual property position related to the development and
 commercialization of microRNA-based products. Rosetta's current programs
 are focused on the development of microRNA-based diagnostic and therapeutic
 products for various cancers and infectious diseases.
     Contact: Media & Investors
     Ron Kamienchick
     T: +972-8-948-4785

SOURCE Rosetta Genomics Ltd